A phase 2, open‐label, randomized, multiple‐dose study evaluating Inarigivir in treatment‐naïve patients with chronic hepatitis B

Author:

Yuen Man‐Fung1ORCID,Chen Chi‐Yi2,Liu Chun‐Jen3,Jeng Wen‐Juei4ORCID,Elkhashab Magdy5,Coffin Carla S.6ORCID,Kim Won7ORCID,Greenbloom Susan8,Ramji Alnoor9ORCID,Lim Young S.10ORCID,Kim Yoon J.11ORCID,Fung Scott K.12,Kim Dong J.13ORCID,Jang Jeong‐Won14ORCID,Lee Kwan Sik15,Iyer Radhakrishnan P.16,Macfarlane Chelsea17,Jackson Kathy18ORCID,Locarnini Stephen A.18,Chan Henry L. Y.19ORCID,Afdhal Nezam H.20

Affiliation:

1. Department of Medicine & State Key Laboratory of Liver Research, Queen Mary Hospital, School of Clinical Medicine The University of Hong Kong Pok Fu Lam Hong Kong

2. Division of Gastroenterology and Hepatology, Department of Medicine Ditmanson Medical Foundation Chiayi Christian Hospital Chiayi Taiwan

3. Department of Internal Medicine and Hepatitis Research Center National Taiwan University College of Medicine and Hospital Taipei Taiwan

4. Department of Gastroenterology and Hepatology, Chang Gung Memorial Hospital, Linkou Medical Center Chang Gung University Taoyuan City Taiwan

5. Toronto Liver Centre, North York General Hospital University of Toronto Toronto Canada

6. Cumming School of Medicine University of Calgary Calgary Canada

7. Department of Internal Medicine, Seoul National University College of Medicine Seoul Metropolitan Government Boramae Medical Center Seoul Seoul South Korea

8. Toronto Digestive Disease Associates Woodbridge Canada

9. Gastrointestinal Research Institute Vancouver Canada

10. Asan Medical Center University of Ulsan College of Medicine Seoul South Korea

11. Department of Internal Medicine and Liver Research Institute Seoul National University College of Medicine Seoul South Korea

12. Department of Medicine, University of Toronto Toronto General Hospital Toronto Canada

13. Hallym University College of Medicine Chuncheon South Korea

14. Seoul St. Mary's Hospital The Catholic University of Korea Seoul South Korea

15. Gangnam Severance Hospital Yonsei University Health System Seoul South Korea

16. RIGImmune, Inc. New Haven Connecticut USA

17. Spring Bank Pharmaceuticals Hopkinton Massachusetts USA

18. Victorian Infectious Diseases Reference Laboratory Royal Melbourne Hospital, The Peter Doherty Institute for Infection and Immunity Melbourne Australia

19. Department of Medicine and Therapeutics The Chinese University of Hong Kong, Prince of Wales Hospital Sha Tin Hong Kong

20. Division of Gastroenterology and Hepatology Beth Israel Deaconess Medical Center Boston Massachusetts USA

Publisher

Wiley

Subject

Hepatology

Reference17 articles.

1. Access to Treatment for Hepatitis B Virus Infection — Worldwide, 2016

2. Chronic hepatitis B virus infection

3. Hepatitis B virus infection

4. EASL‐AASLD HBV treatment endpoints conference faculty. Guidance for design and endpoints of clinical trials in chronic hepatitis B ‐ report from the 2019 EASL‐AASLD HBV treatment endpoints conference;Cornberg M;J Hepatol,2019

Cited by 10 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3